

Early stage profiling of molecule – a key to smart investment

Out of several molecule options available to an Innovator company, which one to take first for time and cost intensive laboratory effort is literally a million dollar question. Information about likely biological behavior of a a molecule having thorough scientific basis is therefore a crying need. Lack of such information often leads to a molecule failing in later development stages, causing financial and time loss, negatively affecting research productivity of the organization.

What is Prometheus?

The Prometheus engagement with VLife is a **360° Druggability Evaluation** of the Innovator's molecules / the molecules they intend to in-license **for informed 'Go – No go' decision**. Under this engagement, VLife with its core technologies, super computing infrastructure and expertise in computational research studies customers' molecules for:

- 1. Undesired target interactions
- 2. Alerts and prediction of various toxicity endpoints such as Mutagenicity, Genotoxicity etc.
- 3. ADME profile prediction

Confidentiality agreement Molecules Preparation Toxicity end point prediction interaction study Analysis with decision support Report

What is Prometheus approach?

As the starting point, the customer provides the molecule structure of the compounds they desire to be evaluated to VLife under confidentiality agreement. VLife then computationally identifies putative targets that are known to deliver undesired toxic effects with VLifeRVHTS technology. Then VLife subjects the compound for rating on various toxicity and ADME parameters using differential evaluation models which are integral part of VLife's NewEdge platform. Based on the in-depth analysis of this extensive study, VLife presents a **360° Druggability Report (360DR)** to the customer which is very useful for 'Go-No go' decision on a molecule and to prioritize molecules for development from among a library of molecules.

What is the benefit of Prometheus to VLife's customers?

A Prometheus engagement with VLife helps customer to take informed 'Go-No Go' decision with confidence on investment in a molecule for laboratory effort. It also provides an informative basis for the prioritization of molecules from among a large molecular library. Prometheus is also highly useful for due-diligence for in-licensing decisions as 360DR presents a sound basis for negotiation. It is important to note that the customer does not have to deploy in-house scientific resources to benefit from Prometheus service from VLife and the IP arising out of a Prometheus engagement remains with the customer.

* Prometheus was a Greek mythological character

